GlassScriptPhysician profile
Cheryl Smith
NPI 1396037966
$68,436.25
in general payments reported to CMS, 2019-2025
53 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,890 · 2020: $16.26 · 2021: $2,902 · 2022: $1,879 · 2023: $6,018 · 2024: $24K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $9,883 · Travel and Lodging: $6,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,945.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,580.00 |
| Food and Beverage | $9,882.77 |
| Travel and Lodging | $6,342.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27,099.95 | 2021-2025 | Ultomiris |
| Ucb, INC. | $21,984.61 | 2023-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Argenx US, INC. | $8,144.15 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $3,896.38 | 2019-2025 | |
| Abbvie INC. | $1,652.72 | 2022-2025 | Botox, Ubrelvy, Duopa |
| Mdd US Operations, LLC | $488.59 | 2022-2024 | Gocovri, Gocovri |
| Pfizer INC. | $426.34 | 2022-2025 | |
| Lilly USA, LLC | $385.99 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $311.27 | 2022-2025 | Vyepti, Rexulti |
| Biogen, INC. | $300.10 | 2021-2025 | Tysabri, Vumerity, Spinraza |
| Emd Serono, INC. | $262.97 | 2022-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $259.83 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $252.70 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $249.86 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $231.55 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $226.24 | 2023-2024 | Wakix |
| Tanabe Pharma America, INC. | $216.54 | 2021-2025 | Radicava |
| Kyowa Kirin, INC. | $201.97 | 2023-2024 | Nourianz |
| Impel Pharmaceuticals INC. | $195.22 | 2023 | Trudhesa |
| Csl Behring | $180.45 | 2023-2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $168.52 | 2023-2024 | Nuedexta, Rexulti |
| Neurelis, INC. | $152.95 | 2022-2025 | Valtoco |
| Octapharma USA, INC. | $93.18 | 2023-2025 | Panzyga |
| Corium, LLC | $83.02 | 2023 | Adlarity |
| Grifols USA, LLC | $73.05 | 2024 | Gamunex-C |
| Averitas Pharma INC. | $67.51 | 2023-2024 | Qutenza |
| Ge Healthcare | $67.10 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $65.50 | 2023-2024 | Lumryz |
| Axsome Therapeutics, INC. | $54.79 | 2025 | Sunosi |
| Celgene Corporation | $47.37 | 2023-2025 | Zeposia |
| Idorsia Pharmaceuticals US INC | $46.91 | 2024-2025 | Quviviq, Quviviq |
| Medtronic, INC. | $44.94 | 2023-2025 | Percept PC Brainsense, Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $40.92 | 2022 | |
| Jazz Pharmaceuticals INC. | $40.46 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $35.51 | 2024 | Belbuca |
| Revance Therapeutics, INC. | $34.23 | 2024 | Daxxify |
| Genzyme Corporation | $33.20 | 2024 | |
| Azurity Pharmaceuticals, INC. | $29.69 | 2023 | Horizant |
| Boston Scientific Corporation | $29.12 | 2025 | Wavewriter Alpha Prime 16 |
| Merz Pharmaceuticals, LLC | $28.62 | 2025 | Xeomin |
| Janssen Scientific Affairs, LLC | $26.84 | 2024 | |
| Amgen INC. | $26.25 | 2025 | Uplizna |
| Strongbridge US INC. | $25.89 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.85 | 2023 | Keveyis |
| Impel Pharmaceuticals LLC | $23.57 | 2024 | Trudhesa |
| C2n Diagnostics, LLC | $22.63 | 2025 | Precivityad2 |
| Philips North America LLC | $16.26 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.89 | 2022 | |
| Eisai INC. | $14.11 | 2023 | |
| Acorda Therapeutics, INC | $13.89 | 2023 | Ampyra, Inbrija |
| Amylyx Pharmaceuticals, INC. | $12.89 | 2023 | Relyvrio |
| Akcea Therapeutics, INC. | $11.16 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.